A call for replicating vector prime-protein boost strategies in HIV vaccine design
- PMID: 15285710
- DOI: 10.1586/14760584.3.4.s105
A call for replicating vector prime-protein boost strategies in HIV vaccine design
Abstract
A key challenge to HIV vaccine development is the integration of HIV proviral DNA into the host genome upon infection. Therefore, an optimal vaccine should block infection within hours of viral exposure, providing 'sterilizing immunity' at mucosal sites and in blood via potent, broadly reactive antibody to the HIV envelope glycoprotein. This is difficult due to the envelope's conformational complexity and sequence diversity. Antibodies that do not completely prevent infection nevertheless could reduce the viral infectious burden, allowing strong cellular immunity to control viremia, delay disease progression and prevent viral transmission, while also providing help for T- and B-cell responses. Rapidly responsive, potent, persistent immunity might best be achieved using prime-boost strategies incorporating a replicating vector and an optimally designed envelope subunit.
Similar articles
-
Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.J Virol. 2004 Jul;78(14):7490-7. doi: 10.1128/JVI.78.14.7490-7497.2004. J Virol. 2004. PMID: 15220422 Free PMC article.
-
HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.J Virol. 2017 Nov 30;91(24):e01077-17. doi: 10.1128/JVI.01077-17. Print 2017 Dec 15. J Virol. 2017. PMID: 29021394 Free PMC article.
-
Long-term maintenance of gp120-specific immune responses by genetic vaccination with the HIV-1 envelope genes linked to the gene encoding Flt-3 ligand.J Immunol. 2003 Mar 1;170(5):2496-507. doi: 10.4049/jimmunol.170.5.2496. J Immunol. 2003. PMID: 12594275
-
How antibodies block HIV infection: paths to an AIDS vaccine.Trends Biochem Sci. 1992 May;17(5):191-6. doi: 10.1016/0968-0004(92)90265-b. Trends Biochem Sci. 1992. PMID: 1350693 Review.
-
Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1.FEMS Immunol Med Microbiol. 2003 Jul 15;37(2-3):129-34. doi: 10.1016/S0928-8244(03)00067-1. FEMS Immunol Med Microbiol. 2003. PMID: 12832116 Review.
Cited by
-
Sequential priming with simian immunodeficiency virus (SIV) DNA vaccines, with or without encoded cytokines, and a replicating adenovirus-SIV recombinant followed by protein boosting does not control a pathogenic SIVmac251 mucosal challenge.J Virol. 2008 Nov;82(21):10911-21. doi: 10.1128/JVI.01129-08. Epub 2008 Aug 27. J Virol. 2008. PMID: 18753198 Free PMC article.
-
Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development.Expert Opin Biol Ther. 2008 Sep;8(9):1347-63. doi: 10.1517/14712598.8.9.1347. Expert Opin Biol Ther. 2008. PMID: 18694354 Free PMC article. Review.
-
Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design.Int Rev Immunol. 2009;28(1):20-48. doi: 10.1080/08830180802684331. Int Rev Immunol. 2009. PMID: 19241252 Free PMC article. Review.
-
Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.J Immunol. 2009 Mar 15;182(6):3718-27. doi: 10.4049/jimmunol.0803115. J Immunol. 2009. PMID: 19265150 Free PMC article.
-
Safety and immunogenicity of an HIV vaccine trial with DNA prime and replicating vaccinia boost.Signal Transduct Target Ther. 2025 Jul 2;10(1):208. doi: 10.1038/s41392-025-02259-y. Signal Transduct Target Ther. 2025. PMID: 40593459 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous